SCHEMBL4213092

SCHEMBL4213092

COc1ccc(CC(=O)NC2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.67
EPHX2 P34913 3/20 0.62
SIGMAR1 Q99720 1/20 0.60
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
STS P08842 2/20 0.55
GPR119 Q8TDV5 3/20 0.53
EPHX1 P07099 1/20 0.52
LMNA P02545 1/20 0.52
MAPT P10636 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
TP53 P04637 1/20 0.52
MCHR1 Q99705 1/20 0.51
CCR5 P51681 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2636671 0.87 MEN1 (0.57) ALDH1A1EPHX2SIGMAR1MEN1KMT2A
SCHEMBL3642671 0.87 MEN1 (0.57) ALDH1A1EPHX2SIGMAR1MEN1KMT2A
SCHEMBL654137 0.87 LMNA (0.60) ALDH1A1SIGMAR1MEN1KMT2ASTS
Bromide SCHEMBL2636355 0.86 MEN1 (0.56) ALDH1A1EPHX2SIGMAR1MEN1KMT2A
SCHEMBL24011150 0.85 SMN1; SMN2 (0.64) ALDH1A1EPHX2MEN1KMT2ASTS
SCHEMBL23387204 0.85 ALDH1A1 (0.68) ALDH1A1EPHX2MEN1KMT2AGPR119
SCHEMBL7381166 0.85 ALDH1A1 (0.69) ALDH1A1EPHX2MEN1KMT2ASTS
SCHEMBL3639970 0.84 GPR119 (0.56) ALDH1A1EPHX2MEN1KMT2ASTS
SCHEMBL28457523 0.83 ALDH1A1 (0.70) ALDH1A1MEN1KMT2ASTSGPR119
SCHEMBL27706952 0.83 SIGMAR1 (0.59) ALDH1A1EPHX2SIGMAR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186921-A1 AZACYCLIC COMPOUNDS ACADIA PHARMACEUTICALS, INC. (US) 2009-07-23 US disclosed
WO-2007124136-A1 USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS ACADIA PHARMACEUTICALS, INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186921-A1 AZACYCLIC COMPOUNDS HTR6, HTR5A, HNMT ALDH1A1 1235/4885EPHX2 1938/4885SIGMAR1 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.